All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Andrew Brunner, Massachusetts General Hospital, Boston, US. We asked, What new treatments are available for high-risk myelodysplastic syndromes (MDS)? What does this mean for patients?
What new treatments are available for high-risk MDS? What does this mean for patients?
In this video, Brunner discusses novel treatment options available for high-risk MDS and the the implications for patients. He also discusses the findings from an ongoing phase II and III trial (NCT03066648), investigating the efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with high-risk MDS.
Your opinion matters
What treatment would you suggest for high risk MDS patients not fit for chemotherapy or HSCT?
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Andrew Brunner, Massachusetts General Hospital, Boston, US. We...
Why is TIM-3 a good target for treating patients with high-risk MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Andrew M. Brunner, Massachusetts General Hospital, Boston, US. We asked, Why...
Subscribe to get the best content related to MDS delivered to your inbox